The activation of each clinical trial involves hundreds of tasks, along with many dependencies and handoffs, some of which may be automated, but many require manual processes.
While Case Report Forms are a main contributor to collected data, non-CRF data such as core laboratory data and central imaging can be critical to any clinical study.
Complicated process of consenting ICU patients can be simplified with a well-designed eConsent platform.
To rebuild trust, companies should focus on transparent, neutral content incorporating medical expertise and regularly seeking HCP feedback.
Virtual trials tools are usually selected early in the protocol development stage, however, due to the COVID-19 crisis, regulators are encouraging sponsors to consider integrating virtual elements into clinical trials already in progress.
Building authentic trust lays at the heart of creating more patient-centric trials.
Statistical methods used via this technique in centralized monitoring.
An overview of patient perceptions of cancer clinical trials and the consent process among those who are currently enrolled in, or who recently completed, a cancer clinical trial.
Life sciences companies challenged by need to minimize health risks without sacrificing data quality during pandemic.
A discussion of how the coronavirus pandemic will have a multitude of impacts on the conduct of trials, as well as on the industry itself.
Looking to the past reminds industry of great strides taken in clinical research for patients.
The rapid evolvement of precision oncology requires real-world data generated at a scale that unlocks insights that can not be provided from clinical trial evidence. Machine learning and large language models can be used to quickly identify information, supporting custom integrated real-world evidence solutions to make informed decisions.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Best practices for assessing publications.
A look at the prevalence of placebo response in clinical trials and how advanced solutions can mitigate the risk it poses to drug development.
How making trial participation easier can reduce the impact on the environment.
Research can reveal vital information about treatments in the long run.
2020 Tufts CSDD study examines relationship between investigative site personnel diversity and study participant diversity.
Evidence from a Phase III cancer trial points to notable advances in data-transfer tech.
Study evaluates the use of AI-supported medical coding module.
Advancing risk-based auditing one step further by identifying the underlying process deficiencies to enable improved corrective and preventive actions.
Fully-integrated, component-based CDMS offers flexibility, customization, and efficiency.
There's no one-size-fits-all approach during the COVID-19 pandemic
Lessons from six months of conducting clinical trials during the COVID-19 pandemic